Merck & Co., Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights - MRK

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Merck & Co., Inc. regarding a class action lawsuit related to misleading statements about the expected revenue from Gardasil sales, which has led to a significant decline in Merck's stock price [1]. Group 1: Allegations and Impact - The lawsuit alleges that Merck provided investors with material information indicating expected revenue of $11 billion from Gardasil sales by 2030, supported by optimistic forecasts about demand in China [1]. - On February 4, 2025, Merck announced it would not achieve the projected$11 billion in sales, citing a halt in shipments to China due to over-inflated inventories and lower-than-expected demand [1]. - Following this announcement, Merck's stock price dropped from $99.79 per share on February 3, 2025, to$90.74 per share on February 4, 2025, representing a decline of over 9% in one day [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of MRK during the specified class period are encouraged to register for the class action, with a deadline of April 14, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's progress [2]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that artificially inflated stock prices [3].